|
gptkbp:instance_of
|
gptkb:fragrance
|
|
gptkbp:bfsLayer
|
6
|
|
gptkbp:bfsParent
|
gptkb:capecitabine
gptkb:Xeloda
gptkb:irinotecan
gptkb:oxaliplatin
|
|
gptkbp:activities
|
inhibits DNA synthesis
|
|
gptkbp:appointed_by
|
intravenous injection
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Adrucil
|
|
gptkbp:can_be_used_with
|
gptkb:leucovorin
gptkb:irinotecan
gptkb:oxaliplatin
|
|
gptkbp:class
|
pyrimidine analog
|
|
gptkbp:clinical_trial
|
Phase II
Phase III
|
|
gptkbp:composed_of
|
gptkb:chemical_compound
|
|
gptkbp:contraindication
|
pregnancy
breastfeeding
severe liver disease
bone marrow suppression
|
|
gptkbp:discovered_by
|
gptkb:1957
gptkb:Charles_Heidelberger
|
|
gptkbp:dissolved
|
soluble in water
|
|
gptkbp:healthcare
|
gptkb:software_framework
gptkb:tablet
gptkb:skincare_product
injection
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
5-fluorouracil
|
|
gptkbp:ingredients
|
C4 H3 F N2 O2
|
|
gptkbp:is_used_for
|
chemotherapy
|
|
gptkbp:lifespan
|
10-20 minutes
|
|
gptkbp:manager
|
oral
topical
|
|
gptkbp:metabolism
|
dihydropyrimidine dehydrogenase
|
|
gptkbp:pharmacokinetics
|
antineoplastic agent
rapidly absorbed
|
|
gptkbp:products
|
gptkb:capecitabine
gptkb:tegafur
uracil
|
|
gptkbp:side_effect
|
gptkb:fandom
nausea
diarrhea
thrombocytopenia
neutropenia
stomatitis
hand-foot syndrome
myelosuppression
|
|
gptkbp:social_structure
|
pyrimidine ring
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:targets
|
thymidylate synthase
|
|
gptkbp:traded_on
|
gptkb:Fluorouracil_Injection
|
|
gptkbp:treatment
|
metastatic colorectal cancer
|
|
gptkbp:type_of
|
51-21-8
|
|
gptkbp:used_in
|
breast cancer treatment
colorectal cancer treatment
pancreatic cancer treatment
stomach cancer treatment
|
|
gptkbp:weight
|
130.1 g/mol
|